Yoshihiro Sato

TL;DR: Treatment with etidronate increases BMD in chronically hospitalized patients poststroke, and may prevent hip fracture, and this study showed that immobilization-induced hypercalcemia and 25-hydroxyvitamin D deficiency contribute to reduced bone mineral density (BMD).

TL;DR: Iwamoto et al. as discussed by the authors published an article entitled "Effects of Vitamin K2 on Osteoporosis, published in Curr Pharm Des 2004; 10(21): 2557-76, by Iwamoto J, Takeda T and Sato Y." has been retracted by the Editorial office of the journal Current Pharmaceutical Design, as the text, data and some figures used/referred in this review article are from sources which have been retracted or under investigation on the basis of data fabrication and falsification, authorship misconduct, duplicate publication, unethical research

TL;DR: The results suggest that there exist elite male athletes who show increased bone resorption and calcium and vitamin D insufficiency, however, there was a discrepancy between vitamin K intake and serum levels of vitamins K1 and K2.

TL;DR: Vitamin K2 mildly attenuated suppression of bone formation (mineralizing surface) and bone erosion caused by risedronate without affecting trabecular bone mass when administered in combination.

TL;DR: The study medications were well tolerated with relatively few adverse events and effective in reducing the risk of a fracture in elderly patients with AD.